Targeted Therapies in Oncology

Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: - Targeted agents of immune checkpoints - Signal-transduction inhibitors - Antiangiogenic agents - Vascular-disrupting agents - Apoptosis modulators - Stem cell inhibitors - Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world. Features Explores targeted agents of immune checkpoints Examines signal-transduction and stem cell inhibitors Discusses antiangiogenic and vascular-disrupting agents Reviews apoptosis modulators Describes tumor profiling for drug development Table of Contents Role of Next-Generation Sequencing Technologies; Siddhartha Devarakonda, Daniel Morgensztern, and Ramaswamy Govindan Signal Transduction Inhibitors of the HER Family; Christina Brzezniak, Corey Carter, Anish Thomas, and Giuseppe Giaccone HER2 Inhibition and Clinical Achievements; Berta Sousa, J. Ribeiro, and Fatima Cardoso Inhibiting the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway; Simona Wagner and Janet E. Dancey BRAF and MEK Inhibitors; Lidia Robert and Antoni Ribas KIT and KIT Inhibitors; Jean-Yves Blay, Armelle Dufresne, Olfa Derbel, and Isabelle Ray-Coquard Targeting the Fibroblast Growth Factor Receptor Pathway in Human Cancer; Maria Vittoria Dieci and Fabrice Andre Anaplastic Lymphoma Kinase; Aparna Rao and Benjamin Solomon MET Inhibitors; Apoorva Chawla, Ravi Salgia, and Victoria M. Villaflor Targeting Stem Cells; Marcello Maugeri-Saccà and Ruggero De Maria The Cancer Super-Chaperone Hsp90: Its Posttranslational Regulation and Drug Targeting; Annerleim Walton-Diaz, Sahar Khan, Jane B. Trepel, Mehdi Mollapour, and Len Neckers Targeting Apoptosis Pathways; Pamela M. Holland, David Reese, and Jeffrey Wiezorek Targeting Angiogenesis; Sophie Postel-Vinay and Jean-Pierre Armand Antivascular Agents; Gianluca Del Conte and Cristiana Sessa Immunotherapy: Monoclonal Antibodies (CTLA4, PD-1, PD-L1, IL-18, and IL-21); Patrick M. Forde and Julie R. Brahmer Vaccine Therapy and Integration with Other Modalities; Benedetto Farsaci, Peter S. Kim, James W. Hodge, Claudia Palena, James L. Gulley, and Jeffrey Schlom Histone Deacetylase Inhibitors as Targeted Therapies; Alexandra Zimmer, Arup Chakraborty, Robert W. Robey, and Susan E. Bates Compounds Targeting Androgen Pathways; Aurelius Omlin, Carmel Pezaro, and Johann de Bono Targeting DNA Repair: PARP and Chk1 Inhibitors; Peter Stephens and Ruth Plummer Inhibitors Targeting Mitosis; Dan L. Sackett, Edina Komlodi-Pasztor, and Tito Fojo